Arcus Biosciences shares dropped 4% after announcing the halt of its Phase 3 STAR-121 lung cancer trial due to futility.
The Independent Data Monitoring Committee recommended stopping the study after a pre‑planned futility analysis, with no new safety issues identified.
Gilead’s option rights under the 2020 collaboration end July 14 2026, and it loses rights to early‑stage pipeline programs.
Arcus retains full rights to casdatifan except for licensed territories in Japan and other Asian markets, excluding China.